This year, researchers unearthed clues to the causes of autism and how to treat it from a variety of sources.
Advances in tiny models of the human brain bared new details about the biology of autism and provided possible platforms for testing therapies. Studies of heart rate put a spotlight on the autonomic nervous system as a potential wellspring of autism traits. And others forged a controversial connection between the gut microbiome and autism.
A few studies revealed important information about the time points at which different forms of autism are amenable to therapy. This year also saw scrutiny of tests used for screening and diagnosis, revealing gaps and limitations in the system for identifying autistic children.
Here are the years top five topics in autism research.
Brain organoids start as mere clusters of stem cells, which then are coaxed to mature into brain cells. This year, the life span of these brains-in-a-dish grew to one year and then nearly two, enabling them to mature and mimic some aspects of the human brain. In the longest-lived organoids, researchers tracked changes in the expression of autism genes. Organoids derived from the skin cells of autistic people have a shortage of cells that suppress brain activity, they found. The finding supports the signaling imbalance theory of autism, which holds that the brains of autistic people are hyper-excitable.
This year, scientists also built tiny replicas of two brain areas bridged by a long fiber tract that might reveal how long-range connections are altered in the brains of people with autism.
Brain organoids spun from people with fragile X syndrome may help explain why some experimental fragile X drugs work in mice but not in people and generate leads for effective therapies. Organoids could provide a platform for testing treatments, too, as researchers can now churn out hundreds of these brain-like blobs in parallel and make them uniform in shape and composition.
More distant applications include studies of consciousness and the effects of microgravity on the brain. In a fledgling sign of the former, brain organoids showed synchronized neuronal firing patterns, some aspects of which look like those in preterm infants.
New evidence emerged tying autism to the workings of the autonomic nervous system, which controls breathing, heart rate and digestion. Differences in the system could explain a range of autism traits, including social difficulties and sensory sensitivity, as well as heart problems and digestive issues.
Many of these differences show up in the heart rate. Heart rate remains steady in autistic people as they breathe instead of the typical pattern of slowing slightly on exhale and quickening on inhale. This discrepancy arises after 18 months of age, around the same time that the conditions core traits emerge. Children with Rett syndrome also have unusual heart-rate patterns.
These differences may persist beyond childhood. One study showed that autistic adults resting heart rates rarely vary; an even heart rate suggests a lack of flexibility in responding to environmental changes.
Autistic children are unusually prone to gastrointestinal problems. This association may not be a coincidence: Certain genetic mutations or alterations in the microbiome the mix of microbes in the intestines may contribute to both autism and gut problems.
Four mouse studies in 2019 offered up fresh evidence some of it controversial to support this idea. In one study, researchers replaced the gut microbes in mice with those from autistic boys. The mice have repetitive behaviors, make fewer vocalizations and spend less time socializing than controls do, providing the first evidence that gut microbes contribute to autism traits.
But within hours of the studys publication, several experts criticized its small sample size and highly variable results. Others found a possible statistical error.
In an unrelated study, researchers revealed that oral doses of Lactobacillus reuteri, a type of gut bacteria found in yogurt and breast milk, boost social behavior in three mouse models of autism. And two other sets of findings suggested that mutations in NLGN3, a high-confidence autism gene, alter gut function. One of them showed that a mutation in this gene disrupts the mices microbiome.
Drugs for autism may be most effective when given during a critical period of brain development. Researchers delineated the windows for treating autism traits in mouse and rat models of the condition.
One study revealed that by the time mice reach adulthood, they have lost their ability to learn from social experiences. Giving adult mice an injection of 3,4-methylenedioxymethamphetamine (MDMA), the active ingredient in ecstasy, reopens the critical window for learning.
In another study, researchers fed the cholesterol drug lovastatin to rat models of fragile X syndrome. The treatment, if given at 4 weeks of age (the rat equivalent of childhood), prevents cognitive problems, the researchers found.
The timing of treatments may be more important for some forms of autism than for others. A study of mice missing UBE3A, the gene mutated in Angelman syndrome, showed that the earlier in life the gene is restored, the more the mice improve.
By contrast, a mutation in the autism gene SCN2A has many of the same effects on neurons when introduced into adolescent mice as it does when it is present from conception. And unpublished results show that correcting an SCN2A mutation in adulthood reverses these problems.
A series of studies this year called into question the accuracy of early screening and revealed racial disparities in autism diagnoses.
Some studies cast doubt on the utility of a widely used screening tool, the Modified Checklist for Autism in Toddlers: The test identifies less than 40 percent of autistic children, and 85 percent of those it does flag do not have autism.
Of the toddlers the test flags, most do not receive follow-up evaluations. And for those who are seen again, a definitive diagnosis may not be possible right away. Some children who screen negative at age 3 meet the diagnostic criteria for autism only after age 5.
Not all children have equal access to autism evaluations, with black and Hispanic children at a disadvantage in several U.S. states. In New Jersey, black children are half as likely as white children to receive an autism assessment by age 3.
About 9 percent of autistic children may outgrow an autism diagnosis but still have other conditions that require support, highlighting the need for continued observation to adapt to their evolving needs.
See original here:
Five hot topics in autism research in 2019 - Spectrum
- New stem cell identified by Sanford Burnham Prebys researchers offers hope to people with rare liver disease - Newswise - October 16th, 2021
- The Impact Of Market Restrictions On The US Stem Cell Biomaterials Market - Med Device Online - October 16th, 2021
- College Student and Retired Teacher to Thank Stem Cell Donors They've Never Met for Saving Their Lives During City of Hope's 45th Bone Marrow... - October 16th, 2021
- Phase 2 Clinical Trial Data of NurOwn in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in... - October 16th, 2021
- Cell therapy strategies for COVID-19: Current approaches and potential applications - Science Advances - August 18th, 2021
- Stem Cell Therapy Market worth $40.3 billion by 2027 Exclusive Report by CoherentMarketInsights - PharmiWeb.com - August 18th, 2021
- Therapeutic Solutions International Reports Superior Neurogenesis Induction in Animal Model of Viral Induced Cognitive Dysfunction Compared to other... - August 18th, 2021
- Atf3 and Rab7b genes drive regeneration in mature cells - Baylor College of Medicine News - August 18th, 2021
- U of T's Medicine by Design helps unite international researchers working to map every human cell - News@UofT - August 18th, 2021
- Mesenchymal Stem Cells Market Witnesses Upward Trend with High Prevalence of Parkinson's Disease The Manomet Current - The Manomet Current - July 22nd, 2021
- BioRestorative Therapies Announces Notice of Allowance for a New Patent Application Related to its Off-the-Shelf ThermoStem Program -... - April 4th, 2021
- Transplant After CD19 CAR T-Cell Therapy Shows Durable Disease Control in Children, Young Adults With B-ALL - Cancer Network - April 4th, 2021
- Stem Cell Assay Market Changing Dynamics Of Competition With Forecast To 2030 The Bisouv Network - The Bisouv Network - April 4th, 2021
- Stem Cell Therapy Market Research Reveals Enhanced Growth During The Forecast Period 2017 2025 FLA News - FLA News - March 8th, 2021
- Adult Stem Cells Market Size, Share, Global Industry Overview, Challenges, Business Overview and Forecast Research Study 2024 (Effect of the COVID-19... - February 17th, 2021
- Be The Match encourages people of color to join bone marrow registry - KING5.com - February 17th, 2021
- Discovery for turning on cell repair in tissues and organs - Monash University - February 17th, 2021
- Manageable Safety Profile Observed in Phase 1 Studies Examining UCART19 for Pediatric and Adult Patients with B-Cell ALL - Cancer Network - February 11th, 2021
- The Very First Signs of an Immune Response Have Been Filmed in a Developing Embryo - ScienceAlert - February 11th, 2021
- JSP191 With Low Dose Irradiation and Fludarabine is Safe and Effective for Patients with MRD+ AML/MDS - Cancer Network - February 9th, 2021
- Creative Bioarray Offers Stem Cell Lines Generation Service for Promoting Scientific Research - Press Release - Digital Journal - February 9th, 2021
- JSP191 With Low Dose Irradiation and Chemotherpy Demonstrates Efficacy and Safety in MRD+ AML/MDS - Targeted Oncology - February 9th, 2021
- Stem Cells Market Value to Reach Around USD 17.79 Bn by 2027 - GlobeNewswire - February 4th, 2021
- Global Adult Stem Cells Market Revenue To Witness Humongous Elevation By 2026 Market Research Store Jumbo News - Jumbo News - February 4th, 2021
- Stem Cell Therapy Market to Score Past US$ 40.3 Billion Valuation by 2027: At a CAGR of 21.1% KSU | The Sentinel Newspaper - KSU | The Sentinel... - February 2nd, 2021
- Reduced Adult Neurogenesis Linked with Alzheimers Disease - The Scientist - February 2nd, 2021
- Regenerative Medicine (Bone and Joint) Market to Score Past US$ 14990.0 Million Valuation by 2027: CMI KSU | The Sentinel Newspaper - KSU | The... - February 2nd, 2021
- Orthopedic Regenerative Medicine Market Size to Witness A Lucrative Growth Over 2020-2027 | Curasan, Inc., Carmell Therapeutics Corporation, Anika... - February 2nd, 2021
- Adult Stem Cells Market Demand, Growth Challenges, Industry Analysis And Forecasts To 2026 | Epistem Ltd.,Globalstem,Mesoblast Ltd.,Brainstorm Cell... - February 2nd, 2021
- ToolGen ties up with 3D bioprinting company to apply induced pluripotent stem cells to gene correction - Aju Business Daily - February 2nd, 2021
- Medicine by Design researchers focus on promoting self-repair of the brain - News@UofT - January 31st, 2021
- Should You Buy Brainstorm Cell Therapeutics Inc (BCLI) Stock on Tuesday? - InvestorsObserver - January 31st, 2021
- Eye stem cell transplant to treat blindness bolsters retinal function in monkeys - FierceBiotech - January 14th, 2021
- Induction of muscle-regenerative multipotent stem cells from human adipocytes by PDGF-AB and 5-azacytidine - Science Advances - January 14th, 2021
- RoosterBio Partners with Sartorius to Advance Cell and Gene Therapy Manufacturing - GlobeNewswire - January 14th, 2021
- Reversing The Aging Clock With Epigenetic Reprogramming - Bio-IT World - January 14th, 2021
- New Models in Organoids Market Open New Vistas in Stem Cell Research for Cancer, Global Valuation to Reach US$ 12.8 Bn by 2030: TMR - PRNewswire - January 12th, 2021
- Health Canada Approves ONUREG (azacitidine tablets), First Maintenance Therapy for Patients in Remission from Acute Myeloid Leukemia - Canada NewsWire - January 12th, 2021
- Stem Cells Market 2020 Research Study including Growth Factors, Types and Application to 2026| Covid-19 Impact - Farming Sector - January 9th, 2021
- The real reason behind goosebumps - Jill Lopez - January 3rd, 2021
- Synthetic lethality across normal tissues is strongly associated with cancer risk, onset, and tumor suppressor specificity - Science Advances - January 3rd, 2021
- New Approaches to the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma - Targeted Oncology - January 3rd, 2021
- CAR T-Cell Therapies Are Set to Expand Into More Hematologic Malignancy Indications - Targeted Oncology - December 26th, 2020
- ElevateBio's HighPassBio Presents on Novel T Cell Receptor Cell Therapy for Leukemia Relapse at 62nd Annual ASH Meeting - Business Wire - December 6th, 2020
- CRISPR and another genetic strategy fix cell defects in two common blood disorders - Science Magazine - December 6th, 2020
- Multiple sclerosis iPS-derived oligodendroglia conserve their properties to functionally interact with axons and glia in vivo - Science Advances - December 6th, 2020
- UCART22 Safe and Active in CD22-Expressing B-Cell ALLs - Targeted Oncology - December 6th, 2020
- Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19) - Cheshire Media - December 6th, 2020
- Stem Cells Market is Expected to Thrive at Impressive CAGR by 2025 - The Haitian-Caribbean News Network - December 5th, 2020
- Stem Cell Assay to Register Substantial Expansion by 2026| Merck, Thermo Fisher Scientific, GE Healthcare - The Haitian-Caribbean News Network - December 5th, 2020
- Stem Cell Therapy Global Market Report 2020-30: Covid 19 Growth and Change - GlobeNewswire - November 25th, 2020
- Functionally distinct resident macrophage subsets differentially shape responses to infection in the bladder - Science Advances - November 25th, 2020
- BioRestorative Therapies Emerges from Chapter 11 Reorganization Other OTC:BRTX - GlobeNewswire - November 20th, 2020
- Jakafi and Dacogen May Improve Overall Survival in Patients with MPN - Curetoday.com - November 20th, 2020
- BRTX-100; the Story of BioRestorative Therapies Inc (OTCMKTS: BRTX) - MicroCap Daily - November 20th, 2020
- As California Passes Prop 14, What Is Stem Cell Research and Why Is It Controversial? - Newsweek - November 16th, 2020
- Organoids mimic the early development of the heart in mouse embryos - BioNews - November 16th, 2020
- Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection - DocWire News - November 16th, 2020
- Cynata Therapeutics (ASX:CYP) begins phase three osteoarthritis trial - The Market Herald - November 16th, 2020
- $ 30.1 billion Worth Cell Expansion Market, Led by Thermo Fisher Scientific Inc, Becton, Dickinson and Company, Terumo BCT and Others. re:Jerusalem -... - November 3rd, 2020
- Impact of COVID-19 on Advanced Wound Care Management Market : Implications on Business Strategies, Countermeasures, Economic Impact - The Think... - November 1st, 2020
- Stem Cells Market 2020 Is Growing with Highest Size, Share of Top Key Players in the Industry and Forecast Survey Till 2024 - Zenit News - October 30th, 2020
- Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease - DocWire News - October 30th, 2020
- JadiCell Stem Cells Licensed by Therapeutic Solutions International for Brain Injury Significantly Increased Survival of COVID-19 Patients in Double... - October 29th, 2020
- Impact Of Covid 19 On Adult Stem Cells Market 2020 Industry Challenges, Business Overview And Forecast Research Study 2026 - PRnews Leader - October 29th, 2020
- APstem Therapeutics Announces Successful FDA INTERACT Meeting Regarding AP-Skin-01, an Off-the-Shelf Allogeneic Stem Cell Product for the Treatment of... - October 29th, 2020
- Why Small Businesses Matter in Wilton (Reimagined): Interventional Orthopedics Connecticut - HamletHub - October 29th, 2020
- Covid-19 Impact On Orthopedic Regenerative Medicine Market 2020 Future Development, Manufacturers, Trends, Share, Size And Forecast to 2027 |... - October 29th, 2020
- Cell Expansion Market a comprehensive study by key players- Thermo Fisher Scientific, Inc, Becton, Dickinson and Company, Terumo BCT, Merck KGaA and... - October 24th, 2020
- Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma... - October 24th, 2020
- What Is the Role of Allogeneic-SCT in Adult Acute Lymphoblastic Leukemia in the Era of Targeted Therapies? - Targeted Oncology - October 21st, 2020
- Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19) - Eurowire - October 17th, 2020
- Global Stem Cell Therapy Market (Covid-19 updated report), Trends, Top Manufacturers, Exponential Growth and Forecast 2020 to 2027 By Reportspedia -... - October 17th, 2020
- Was Trump's Regeneron 'Cure' Developed Using Stem Cells and Fetal Tissues? - Snopes.com - October 13th, 2020
- The complicated story of Trump's COVID treatment, stem cells and abortion politics - Baptist News Global - October 13th, 2020
- BrainStorm to Present at the 2020 Cell & Gene Meeting on the Mesa - PRNewswire - October 13th, 2020
- Human heart organoids provide unmatched insight into cardiac disease and dysfunction - BioWorld Online - October 13th, 2020
- Sickle Cell Disease Association of America and Aruvant Sciences Forge New Partnership to Educate Around Gene Therapy - Herald-Mail Media - October 13th, 2020
- Q Stock; The Rise of BioRestorative Therapies Inc (OTCMKTS: BRTXQ) - MicroCap Daily - October 8th, 2020
- A Uniquely Patient-Focused Take on Treating AML in Older Adults - Medscape - October 8th, 2020